{"slideshow_credits": null, "snippet": "The companies developing the treatment, called bapineuzumab, said it did not improve cognition or daily functioning compared with a placebo.", "abstract": "Johnson & Johnson and Pfizer announce they are halting development of closely watched Alzheimer's drug bapineuzumab after two clinical trials failed to show that it was effective in patients with mild to moderate forms of the disease.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/08/07/business/alzheimers-drug-trials-halted.html", "lead_paragraph": "The companies developing the treatment, called bapineuzumab, said it did not improve cognition or daily functioning compared with a placebo.", "headline": {"seo": "Alzheimer&#8217;s Drug Trials Halted by Johnson &amp; Johnson and Pfizer", "main": "Trials for Alzheimer&#8217;s Drug Halted After Poor Results", "print_headline": "Trials for Alzheimer\u2019s Drug Halted After Poor Results"}, "_id": "53f9925238f0d84410bcb11a", "word_count": "297", "multimedia": [], "pub_date": "2012-08-07T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Alzheimer's Disease", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Johnson & Johnson", "name": "organizations", "is_major": "Y", "rank": "3"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Pfizer Inc", "name": "organizations", "is_major": "Y", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}